Company Information
CIN
Status
Date of Incorporation
27 August 2003
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 September 2023
Paid Up Capital
52,000,000
Authorised Capital
100,000,000
Directors
Laxmi Prasuna Manne
Director/Designated Partner
over 2 years ago
over 2 years ago
Satyanarayana Reddy Manne
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Vinod Kumar Chawla
Director/Designated Partner
about 3 years ago
about 3 years ago
Bharat Reddy Chintapally
Director/Designated Partner
almost 19 years ago
almost 19 years ago
Patents
Abstract
The present invention relates to novel crystalline form of 5-fluoro-3-phenyl-2-[(lS)-l-(9H-purin-6-ylamino)propyl]quinazolin-4(3H)-one compound of formula-1 and process for its preparation thereof, represented by the following structural formula:
The present invention relates to a pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts.
The present invention relates to an amorphous form of 4-methyl-N-[3-(4-methyl-1H-imidazol-l-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide compound of formula-1, which is represented by the following structural formula
The present invention relates to novel polymorphs of (i?)-8-chloro-l-methyl-2,3,4,5-tetrahydro-l#-3-benzazepine hydrochloride which is represented by structural formula-1 and process for its preparation.
The present invention relates to a process for the preparation of Trisodium (4-{[(lS,3R)-l-([l,l"-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(N-pentanoyl-N-{[2"-(lH-tetrazoI-l-id-5-yl)[l,r-biphenylJ-4-yl]methyl}-L-vallnate) represented by the following structural formula-1 and its poly...
The present invention relates to a process for the preparation of highly pure 5-[(1RS)-2-cyclopropyl-l-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c] pyridin-2-yl acetate as well as novel process for its intermediate
The present invention relates to improved processes for the preparation of compounds of formula-I and II, which are key intermediates for the preparation of Rosuvastatin and its pharmaceutically acceptable salts.
The present invention relates to a novel process for the preparation of Isopropyl (Z)-7-[(lR,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]-cyclopentyl]-5-heptenoate represented by structural formula-1. The present invention also relates to novel intermediates for the preparation of Isopropyl (Z)-7-[(lR,2...
The present invention relates to novel salts of benzimidazole derivatives, preferably mesylate salt of benzimidazole derivatives represented by the following structural formulas, which are useful intermediates in the synthesis of pure l-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-yl...
The present invention relates to amorphous solid dispersions of 5-chloro-N4-[2-[(l-methylethyl)sulfonyl]phenyl]-N 2,4-pyrimidinediamine compound of formula-1, represented by the following structure:
The present invention relates to a process for the preparation of Clofarabine compound of formula-1.A process for the preparation of pure Clofarabine compound of formula-1, comprising of;
a) Reacting the 2-Deoxy-2-fluoro-l,2,5-tri-0-benzoyl-D-ribofuranose compound of
formula-2
BzO \ J
BzCf F
Formula-2 wit...
The present invention relates to crystalline polymorph of N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4".(trifluoromethyl)[l, 1 "-biphenyl]-2-yl]carbonyl] amino]-1 -piperidinyl]butyl]-9H-fluorene-9-carboxamide methanesulfonate salt represented by the following structural formula-la and process for preparation thereof.
...
ABSTRACT
The present invention relates to process for the preparation of l-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide represented by the following structural formula-1 a and polymorphs thereof.
The present invention relates to Amorphous form of N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-ftiranyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its process for preparation.
The present invention relates to an improved process for the preparation of crystalline polymorphs of Rifaximin compound represented by the following structural formula-1.
Abstract
The present invention relates to an improved process for the preparation of N-[6-( cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4" -(trifluoromethoxy) carboxamide diphosphate, represented by the following structural formula
The present invention relates to an improved process for the preparation of crystalline N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-]-piperazinyl]-2-methyl-4-pyrimidinyl]-amino]-5-thiazolecarboxamide monohydrate compound represented by the following structural formula-la.
The present invention relates to novel & improved processes for the preparation of antiarrhythmic agent.
The present invention relates to novel crystalline form of 5-fluoro-3-phenyl-2-[(l S)-1-
(9I-I-purin—6-ylamino)propyl]quinazolin-4(3H)-one compound of formula-1 and process for its
preparation thereof, represented by the following structural
Abstract
The present invention relates to an improved process for the preparation of N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine represented by the folio wing structural formula-1 and its pharmaceutically acceptable salts.
The present invention relates to novel crystalline polymorph of N-[2-[(lS)-l-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]2,3-dihydro-l,3-dioxo-lH-isoindol-4-yl] acetamide represented by the following structural formula-1 and process for its preparation.
The present invention provides a process for the preparation of crystalline form-XLI of N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-lH-indazol-6-ylsulfanyl]-benzamide compound of formula-1, which is represented by the following structural formula
The present invention relates to process for the preparation of (laR,2S,5R,5aS,6S£a3,9RA
The present invention relates to novel process for the preparation of (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-cyclopentylpropanenitriIe phosphate compound of formula-1 represented by the following structural formula:
The present invention relates to formic acid salt as well as its crystalline form of antidepressant drug i.e., 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofurancarboxamide compound of formula-1, which is useful in the preparation of 5-[4-[4-(5-cyano-lH-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran ca...
The present invention relates to an improved process for the preparation of 5-[[[(2S)-
2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H
imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid compound of formula-1,
represented by the following structural formula:
...
The present invention relates to novel polymorphs of 5-[[[(2S)-2-amino-3-[4-(amino
carbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]
amino]methyl]-2-methoxybenzoic acid compound of formula-1, represented by the following
structural formula:
The present invention relates to a process for the preparation of (lS)-l,5-anhydro-l-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol which is represented by the following structural formula-1 and its glycerol solvate.
The present invention relates to novel crystalline polymorphs of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-l-piperazinyl)propoxy]-3-quinoline carbonitrile represented by the following structural formula-1 and process for preparation thereof.
The present invention relates to a process for the preparation of 6,11-dihydro-l 1-(1 -methyl-4-piperidinylidene)-5H-imidazo[2,1 -b] [3 ] benzazepine-3 -carboxaldehyde compound of formula-1.
The present invention also provides novel crystalline polymorph of compound of formula-1 and process for its preparation....
The present invention relates to an improved process for the preparation of GABA analogue represented by the following structural formula-1
The present invention relates to novel process for the preparation of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-moipholinyl)phenyl]-l,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide represented by the following structural formula-1.
o Formula-1
The present invention relates to an improved process for the preparation of 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-y1- carboxylicacid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide represented by the following structural formula-1.
The present invention provides a process for the preparation of intermediate compounds used for the preparation of (lS,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-l-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile and its pharmaceutically acceptable salts thereof, represented by the following structural formula....
Abstract
The present invention relates to novel processes for the preparation l,3-Thiazol-5-ylmethyl[(2R,5R)-5-{[(2S)-2-K^
carbamoyl)amino]-4-(morpholin-4-yl)butanoyl]amino}-l,6-diphenylhexan-2-yl] carbamate having the following structural formula-1 and it's intermediates thereof.
Abstract
The present invention relates to a solid dispersion of l,3-Thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-[(methy^^
amino]-4-(morphoIin-4-yl)butanoyl]amino}-l,6-diphenylhexan-2-yl] carbamate having the following structural formula-1 with one or more pharmaceutical acceptable carrier and process for their preparat...
The present invention relates to novel pyrimidine derivatives, process for their preparation and their use in the preparation of bis[(E)-7-[4( 4-fluorophenyl)-6-isopropyl-2[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)3,5-dihydroxyhept-6-enoic acid] or its pharmaceutically acceptable salts thereof.
...
The present invention relates to novel polymorphs and novel intermediate for l-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1 -yl)phenyl]-4,5,6,7-tetrahydro-1 H-pyrazolo [3,4-c]pyridine-3-carboxamide represented by the following structural formula-1.
Formula-1
The present invention relates to a process for the preparation of ((3S,5R)-5-((lH-1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3 -yl)methyl-4-methyl benzenesulfonate compound of formula-1, which is a useful intermediate for the preparation of Triazole Antifungal drug and represented by the follo...
The present invention relates to pharmaceutical composition of moxifloxacin, its salts and/or hydrates and also relates to the method of preparation of the pharmaceutical composition.
The present invention relates to novel process for the preparation of 3-[(li?,2i?)-3-(dimethylamino)-l-ethyl-2-methylpropyl]phenol represented by structural formula-1 and its hydrochloride salt. The present invention also provides novel intermediates which are useful in the preparation of 3-[(lR,2R)-3-(dimethylamino...
The present invention relates to an amorphous solid dispersion of (15)-l,5-anhydro-l-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-P-glucitol compound of formula-1, and its process for the preparation thereof. The compound of formula-1 is represented by the following structural formula:
...
An improved process for the preparation of butyroxymethyl methyl4-(2,,3"-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate compound of formula-1. The present invention also relates to novel crystalline forms of compound of formula-1 and its intermediates thereof.
Formula-1
The present invention relates to amorphous form of 5-chloro-N4-[2-[(l-meihylcthyl)
sulfonyl]phenyl]-N2-[5-methyl-2-(l-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidine diamine compound of formula-1, represented by the following structure.
Process For The Preparation Of N Butyl 2 ((4 R,6 S) 6 Formyl 2, 2 Dimethyl 1,3 Dioxan 4 Yl)acetamide
The present invention relates to a novel process for the preparation of N-butyl-2-((4R,6S)-6-formyl-2,2-dimethyl-l,3-dioxan-4-yl)acetamide compound of formula-1.
The present invention provides a novel polymorphic form of l-[(2,6-difluorophenyl)methyl]-lH-l,2,3-triazole-4-carboxamide compound represented by the following structural formula-1 and process for its preparation.
The present invention relates to amorphous form of 5-[[[(2S)-2-amino-3-[4-(amino
carbonyD-Z.6-dimethylphenyl]-1-oxopropyl][(1S)-l-(4-phenyI-lH-imidazol-2-yl)ethyl]amino]
methy1]-2-methoxy benzoic acidpompound of formulg—I, represented by the following structure:
The present invention relates to amorphous form of 5-[[[(2S)-2-amino-3-[4-(amino carbonyI)-2,6-dimethylphenyl]-1 -oxopropyl] [(1S)-1 -(4-phenyl-1 H-irnidazol-2-yl)ethyl]amino] methyl]-2-methoxy benzoic acid compound of formula-1, represented by the following structure.
Abstract
The present invention relates to solid state forms of 5-fluoro-3-phenyl-2-[(lS)-1-(9H" purin-6-ylamino)propyl]quinazolin-4(3H)-one and salts-thereof-compound~of~formula-1 anc process for its preparation thereof, which is represented by the following structural formula
The present invention relates to novel crystalline polymorphs of l-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide represented by the following structural formula-la and process for preparation thereof.
The present invention relates, to a pharmaceutical composition of N-(3,5-
dichloropyridin-4-yl)-3 -cyclopropylmethoxy-4-difluoromethoxy-benzamide and its
preparation thereof. Further, the stable pharmaceutical composition of the present invention is for the treatment of chronic obstructive pulmonary dise...
The present invention relates to an improved process for the preparation of crystalline methanol solvate, ethanol solvate and crystalline Form-Ill of 4-(4-{3-[4-Chloro-3-(trifluorom,ethyl)phehyl]ureido}phenoxy)-N-2-methylpyridine-2-carboxamide 4-methyl benzenesulfonate compound of formula-2, which is represented by ...
The present invention relates to a process for the preparation of anticoagulant drug i.e, 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene carboxamide represented by the structural formula-1. Further, the present invention also relates to novel intermediates, which ar...
The present invention relates to an improved process for the preparation of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzene sulfonamide or its pharmaceutically acceptable salts preferably hydrochloride salt represented by the compound of formula-I.
Formula-I
...
The present invention relates to an improved process for the preparation of 1-[(3R)-3-
[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-
1-one compound of formula-1 and its polymorphs thereof, which is represented by the
following structural formula:
ABSTRACT:The present invention relates to an improved process for the preparation of ((2R,3R)-2-(2,4-di fluorophenyl)-3-(4-methylenepiperidin-1 yl)-1 -(IH-1,2,4-triazol-1 -yl)butan-2-ol) compound of formula-1 and its salts thereof.
ABSTRACT:
The present invention relates to a novel process for the preparation of methyl[(2S)-1-{(6S)-6-(5-(9,9-difluoro-7-{2-[(lR,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbu-tanoyl} -2-azabicyclo[2.2.1 ]hept-3-yl]-1 H-benzimidazol-6-yl} -9H-ftuoren-2-yl)-1 H-imidazol -2-yl]-5-azaspiro[2.4.]hept-5-yl}-3-me...
The present invention relates to a novel process for the preparation of DPP-IV inhibitors
Abstract
The present invention relates to novel process for the preparation of propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-lH-pyrrolo[253-b]pyridine-3-carbonyl]-294-difluoro-phenyl}-amide compound of formula-1, represented by thej following structure:
The present invention relates to process for the preparation of (1 S,3 S,7S, 1 OR, 11S, 12S, 16R)-7,11 -dihydroxy-8,8,10,12,16-pentamethyl-3-[(lE)-1 -methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione reesented by the following structural formula-1.
Formula-1 The pres...
The present invention provides a novel process for the preparation of l-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-lH-indole-7-carboxamide compound represented by the following structural formula-1.
The present invention relates to 2-(2-aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide monohydrochloride compound of formula-la, its hydrates, polymorphs and process for preparation thereof.
The present invention relates to amorphous solid dispersion comprising (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-4-fLuoro-3-hydroxy-4-methyl tetrahydrofuran-2-yl)methoxy)-(phenoxy)phosphorylamino)propanoate represented by the following structural formula-1 and at least one pha...
The present invention relates to novel process for the preparation of (2S)-N-((S)-l-((S)-4-methyl-1 -((R)-2-methyloxiran-2-yl)-1 -oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide represented by the following structural formula-1.
The present invention relates to novel salts of 2-(5-((pyrrolidin-l-ylsulfonyl)methyl)-lH-indol-3-yl)ethanamine, its use and process for their preparation.
Abstract
The present invention relates to novel polymorph of (lS)-1,S-anhydro-1-[3-[[5—(4-
fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol compound of formula-1, and its
process for the preparation. thereof. The compound of formula-1 is represented by the
following structural formula:
...
The present invention relates to polymorphs of 5-[[[(2S)-2-amino-3-[4-(amino carbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl] amino]methyl]-2-methoxybenzoic acid compound of formula-1, represented by the following structure:
Formula-1
An improved process for the preparation of (S)-N, N-dimethyl-3-(naphthalen-l-yloxy)-l-phenylpropan-1-amine hydrochloride compound of formula-A.
The present invention related to novel crystalline forms of methyl [(2S)-1-{(6S)-6-[5-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo [2.2.1]hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4] hept-5-yl}-3-methyl-1-oxobutan-2-yl]carb...
The present invention related to a novel process for the preparation of (lR,2R,3aS,9aS)-[[2,3,3a,4,9,9a-Hexahydro-2-hydroxy-l-[(3S)-3-hydroxyoctyl]-lH-benz[fj inden-5-yl]oxy]acetic acid represented by structural formula-1 and also its pharmaceutically acceptable salts, preferably sodium salt represented by structura...
The present invention relates to novel polymorphs of N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its process for the preparation.
The present invention relates to an oral pharmaceutical composition (-) modafinil.
Abstract
The present invention relates to a novel polymorph of isobutyric acid 2-((R)-3-diisopropylamino-1 -phenylpropyl)-4-(hydroxymethyl)phenyl ester hydrochloride represented by the following structural formula-la and process for its preparation.
The present invention relates to process for the preparation of (ZS)-N-((S)-1-((S_)-4-
methyl—1-((R)-2-methyloxiran-2-yl)-l-oxopentan-Z-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-
morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide represented by the following
structural formula-1.
The present invention relates to a process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1 -[(2S)-1 -hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid represented by the following structural formula-1 and pharmaceutically acceptable salts thereof.
The present invention relates to amorphous form of N-[6-(cis-2,6-dimethylmorpholin-
4-yl)pyridine-3-yl]-2-methyl-4"-(trifluoromethoxy) [l,l"-biphenyl]-3-carboxamide
diphosphate compound of formula-la and process for its preparation thereof, which is represented by the following structural formula
CH3
F3C (i ^ ...
The present invention provides processes for the preparation of (lS,3S,5S)-2-[(2S)-2-Amino-2-(3-hydroxyadamantan-l-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.
The present invention relates to an improved process for the preparation of (1S)-1,5-anhydro-1 -[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-P-glucitol compound of formula-1, represented by the following structural formula.
The present invention relates to process for the preparation of (4R,12aS)-9-{[(2,4-difluorophenyl)methyl]carbamoy
[r,2,:4s5]pyrazino[2,l-b][l,3]pxazin-7-ol represented by the following structural formula-1 and pharmaceutical^ acceptable salts thereof.
The present invention relates to a novel crystalline form of anti-hyperuricemia drug, i.e. 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid represented by structure formula-1 and its process for preparation.
The present invention provides a process for the preparation of l-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-lH-indole-7-carboxamide compound represented by the following structural formula-1.
The present invention relates to a novel process for the preparation of crystalline l-(3-hydroxypropyl)-5-[(2R)-({2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino) propyl] -2,3-dihydro-lH-indole-7-carboxamide and its pharmaceutical composition.
The present invention relates to a process for the preparation of (S)-l0-acetoxy-10,11 -dihydro-5H-dibenz[b,fJazepine-5-carboxamide compound of formula-1.
The present invention relates to a process for the preparation of (2a,5p,7p,10p,13a)-4-acetoxy-13-({(2R,3S)-3-[(tertbutoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-l-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-ll-en-2-yl benzoate compound of formula-1 and intermediates thereof.
Formula-1
...
The present invention relates to process for the preparation of D-glucitol, 1,5-anhydro-l-C-[4-chloro-3-[[4-[[(3,S)-tetrahydro-3-furanyl]oxy]phenyl] methyljphenyl]-, (IS) and its polymorphs of formula-1.
The present invention relates to an improved process for the preparation of 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-l-oxopropyl][(lS)-l-(4-phenyl-lH-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid compound of formula-1, represented by the following structure.
The present invention relates to novel and improved processes for the preparation of 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1.
The present invention relates to a process for the preparation of an orally active renin inhibitor such as (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide compound of formula-1 or its salt thereof.
The present invention is directed to oral solid pharmaceutical dosage form comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-l,3-diol hydrochloride and method of making thereof.
ABSTRACT
The present invention relates to novel crystalline polymorphs of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-l-piperazinyl)propoxy]-3-quinoline carbonitrile represented by the following structural formula-1 and process for preparation thereof.
The present invention provides a novel process for the preparation of (lR,2R,3aS,9aS)-[[2,3,3a,4,9,9a-Hexahydro-2-hydroxy-l-[(3S)-3-hydroxyoctyl]-lH-benz[f]inden-5-yl] oxy]acetic acid represented by structural formula-1 and its pharmaceutically acceptable acid addition salts, preferably its sodium salt ...
The present invention relates to process for the preparation of N-[5-(4-bromophenyl)-
6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N"-propylsulfamide represented by the following structural formula-1.
The present invention relates to an improved process for the preparation of an orally active renin inhibitor such as (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyi-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide hemifumarate represented by the following structural formula-la. Furt...
The present invention provides novel polymorphic forms of (5-methyl-2-oxo-l,3-dioxol- 4-yl)methyl 2-ethoxy-1 - {[2"-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl] methyl}-lH-benzimidazole-7-carboxylic acid compound of formula-2, its derivatives and their pharmaceutically acceptable salts thereof.
...
ABSTRACT
The present invention relates to‘ amorphous form of N-[2-[(1S)-1-(3-ethoxy—4-
met_hoxyphenyl)-2-(methy1sulfonyl)ethy1]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide
represented by the following structural forrnula-1 and process for its preparation.
Abstract; The present invention relates to an improved process for the preparation of ((2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1 yl)-1 -(1H-1,2,4-triazol-1 -yl)butan-2-ol) compound of formula-1, its salts and its crystalline forms thereof.
The present invention provides an improved process for the preparation of (S)-4-[(3-chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-l-pyrrolidinyl]-N-(2-pyrimidinyl methyl)-5-pyrimidine carboxamide which is represented by the following structural formula-1.
Formula-1
The present invention relates to a process for the preparation of 1-Deoxy-
l(methylamino)-D-glucitol [3-[[(2R,3S)-2-[(1R)-l-[3,5-bis(trifluoromethyl)phenyl]
ethoxy]-3-(4-fluorophenyl)4-morpholinyl]methyl]-2,5-dihydro-5-oxo- 1H-1,2,4-triazol-1 -yl]phosphonate (2:1), having the following structural formula-1.
...
The present invention relates to an improved process for the preparation of propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-lH-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compound of formula-1, represented by the following structure:
The present invention relates to a process for the preparation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide compound of formula-1, and its crystalline polymorph-I which is represented by the following structural formula:
The present invention relates to novel crystalline polymorphs of l-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide represented by the following structural formula-1 a and process for preparation thereof.
The present invention relates to a process for the preparation (lR,5S)-N-[3-amino-1 -(cyclobutylmethyl)-2,3 -dioxopropyl]-3 - [2(S)- [ [ [(1,1 -dimethylethyl)amino] carbonyl]amino]-3,3-dimethyl-l-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide represented by structural formula-1. The present inventi...
The present invention relates to novel process for the preparation of (lS,3aR,6aS)-2-[(2S)-2-({(2S)-2-cyclohexyl-2-[(pyrazin-2-ylcarbonyl)amino]acetyl}amino)-3,3-dimethyl butanoyl]-N-[(3 S)-1 -(cyclopropylamino)-1,2-dioxohexan-3 -yl]-3,3 a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-l-carboxamide compound represented...
The present invention relates to an improved process for the preparation of (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropionic acid and its intermediate compounds. The (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropionic acid is represented by the following structura...
The present invention relates to process for the préparation of N-[2-(7-methoxy-l - naphthyl)ethyl]acetamide compound of formula-1 and novel crystalline forms of its intermediate compounds.
Abstract
The present invention relates to acid addition salts of 5-chloro-N4-[2-[(1-methylethyl) sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine and process for its preparation thereof compound of formula-1, represented by the following structure:
...
Abstract
The present invention provides an improved process for the preparation of (±)-2-hydroxy-5-[( IRS)-1 -hydroxy-2-[[( lRS)-2-(4-methoxyphenyl)-1 methylethyl]-amino]ethyl] formanilide compound of formula-1 and its salts.
The present invention relates to a process for the preparation of intermediate compounds of(lR,5S)-N-[3-amino-l-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(l,l-dimethylethyl) amino]carbonyl]amino]-3,3-dimethyl-l-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide represented by structural formula-A....
The present invention provides an improved process for the preparation of antiarrhythmic agent represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.
Formula-1
The present invention relates to a pharmaceutical composition of N-(3,5-dichloropyridin-4-yl)-3 -cyclopropylmethoxy-4-difluoromethoxy-benzamide, which is useful for the treatment of chronic obstructive pulmonary disease (COPD).
The present invention is relates to an improved process for the preparation of (1S,4£7Z,10S,16£,21J?)^ tetraazabi- cyclo[8.7.6]tricos-16-ene-3,659,19,22-pentone of formula I
The present invention relates to an improved process for the preparation of N-[2-(7-methoxy-l-naphthyl)ethyl]acetamide, represented by the following structural formula-1. Further, the present invention also relates to novel process for the purification of intermediate compounds of said formula-1.
Formula-1
...
The present invention provides an improved process for the preparation of 2-ethylamino-4-methyl-4-phenyl-6-chloro-4H-3,l-benzoxazine compound represented by the following structural formula-1 and its pharmaceutically acceptable salts.
Formula-1
Abstract
The present invention relates to a process for the preparation of N-[2-hydroxy-5-[(lR)-l-hydroxy-2-[[(lR)-2(4-methoxyphenyl)-l-methylethyl]amino]ethyl] phenyl]-formamide tartrate compound of formula-1.
The present invention provides a stable crystalline form-B of 3-[(1R,2R)-3-(dimethylamino)-l-ethyl-2-methylpropyl]phenol mono hydrochloride compound of formula-la and its process for the preparation.
Formula-la
The present invention relates to an improved process for the preparation of (R)-N-benzyl-2-Acetamido-3-methoxypropionamide compound of formula-1 represented as below
Improved Process For The Preparation Of 7 {4 [4 (2,3 Dichlorophenyl) Piperazin 1 Yl]Butoxy} 2 Oxo 3,
The present invention relates to improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2-oxo-3,4-dihydro-2H-quinolin-1-yl)methyl dodecanoate compound of formula-1, which is represented by the following structural formula
The present invention relates to an improved process for the preparation of Z-2-aminomethyl-1-phenyl-N,N-diethyl cyclopropane carboxamide compound of formula-1 and its pharmaceutically acceptable salts.
The present invention relates to solid state forms of 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N44-(2-methylphenyl)-6-(4-methylpiperazin-l-yl)pyridin-3-yl]propanamide represented by the following structural formula-1 and process for preparation thereof
The present invention relates to a novel process for the preparation of amorphous 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)tetrahydro-5-(lH-l,2,4-triazol-l-ylmethyl)-3furanyl]methoxy]phenyl]-l-piperazinyl]phenyl]-2-[(lS,2S)-l-ethyl-2-hydroxypropyl]-2,4-dihydro-3H-l,2,4-triazol-3-one compound of formula-1.
...
The present invention relates to processes for the preparation of intermediate compounds, which are useful for the preparation of 8-[(3R)-3-amino-l-piperidinyl]-7-(2-butyn-l-yI)-3,7- dihydro-3-methyl-l-[(4-methyl-2-quinazolinyl)methyl]-lH-purine-2,6-dione compound represented by the following structural formula-1.
...
The present invention relates to an improved process for the preparation of 3-isobutyry]
2-isopropyl pyrazolo[l,5-a] pyridine compound represented by the structural formula-1
The present invention relates to an improved process for the preparation of ((3S,5R)-5-((lH-l,2,4-triazol-l-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl) methyl-4-methyl benzene sulfonate compound of formula-1 through novel intermediates.
The present invention relates to crystalline forms of Tapentadol salts and their processes for the preparation. The structural formula of Tapentadol salts is represented
The present invention relates to process for the preparation of (1S,3aR,6aS)-2-[(2S)-2-({(2S)-2-cyclohexyl-2-[(pyrazin-2-ylcarbonyl)amino]acetyl}amino)-3,3-dimethylbutanoyl]-N-[(3 S)-1 -(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1 H-cyclopenta[c] pyrrole-1-carboxamide compound represented by the...
The present invention relates to acid-addition salts of (9RS)-3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)piperidin-l-yl]ethyl]-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido [1,2-a] pyrimidin-9-yl hexadecanoate compound represented by the following structural formula-1, their polymorphs and processes for their preparation...
The present invention relates to novel crystalline form of N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide compound of formula-1 and process for its preparation.
represented by the following structural formula-1.
The present invention also provides novel intermediate compounds useful for the preparation of compound of formula-1.
The present invention relates to an improved process for the preparation of (lR,5S)-N-[3-amino-l -(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(l ,1 -dimethyl ethyl)amino]carbonyl]amino]-3,3-dimethyl-l-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0] hexan-2(S)-carboxamide compound represented by the following structura...
The present invention relates to process for the preparation of 7-chloro-l-methyl-5-phenyl-lH-l,5-benzodiazepine-2,4(3H,5H)-dione represented by the following structural formula-1.
The present invention relates to novel process for the preparation of (Z)-isopropyl 7-((lR,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-l-enyl) cyclopentyl)hept-5-enoate represented by the compound of formula-I and its novel intermediates thereof.
The present invention relates to an improved process for the preparation of (±)-[ 1 R(S),2S(R)]-2-(aminomethyl)-N,N-diethyl-1 -phenylcyclopropane carboxamide, which is represented by the structural formula-1 and its pharmaceutically acceptable salts thereof.
The present invention relates to novel process for the preparation of 5-chloro-N4-[2-[(l-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(l-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine compound of formula-1 and its pharmaceutically acceptable salts thereof, represented by the following structure:
...
The present invention relates to a process for the preparation of anticoagulant drug i.e, 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl} methyl)-2-thiophene carboxamide represented by the following structural formula-1.
Formula-1
The present invention relates to a process for the preparation of antipsychotic drug i.e., (3aRS, 12bi?5)-5-Chloro-2-methyl-2,3,3a, 12b-tetrahydro-liMbenzo[2,3:6,7]oxepino [4,5-c]pyrrole maleate compound of formula-1.
The present invention relates to novel polymorph of metopimazine compound of formula-1 and process for it"s preparation.
The present invention relates to novel crystalline forms of antidepressant drug i.e., 5-[4-[4-(5-cyano- lH-indol-3-yl) butyl]-1 -piperazinyl]-2-benzofuran carboxamide compound of formula-1 represented by the following structural formula-1.
The present invention relates to novel and orally disintegrating sublingual pharmaceutical composition comprising asenapine and its pharmaceutically acceptable salts thereof, and methods of preparing the same. In particular, the invention relates to granulated pharmaceutical composition of asenapine and its salts th...
ABSTRACT
The present invention relates to an improved process for the preparation of nebivolol hydrochloride compound of formula-1 And also relates to a novel organic acid salts of benzyl protected nebivolol compound offormuia-7.
The present invention relates to a novel process for the preparation of bosentan compound of formula-1.
The present invention relates to an improved process for the preparation of 1H-
Benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-l -methyl-,
monohydrochloride represented by the following structural formula-1.
The present invention relates to a novel process for the preparation of Dexlansoprazole compound of formula-1 and its pharmaceutically acceptable salts thereof.
The present invention relates to purification method for 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-ylcarboxylicacid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide methanesulfonate represented by the following structural formula-1.
The present invention relates to stable parenteral pharmaceutical composition comprising of 3-[(li?,2i?)-3-(dimethylamino)-l-ethyl-2-methylpropyl]phenol or its pharmaceutically acceptable salts; preferably hydrochloride. Further, the present invention relates to a process for its preparation thereof.
...
The present invention relates to an improved process for the preparation of (R)-N-benzyl-2-Acetamido-3-inethoxypropionamide compound of formula-l represented by the following structural formula
The present invention relates to processes for the preparation of 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile represented by the following structural formula-1 and its pharmaceutically acceptable acid-addition salts.
The present invention provides an improved and novel processes for the preparation of 2-amino-2-[2-(4-octylphenyl)ethyl]propan-l,3-diol hydrochloride compound represented by the following structural formula-la.
The present invention relates to novel and improved processes for the preparation of sitagliptin compound of formula-1, its pharmaceutically acceptable salts as well as their intermediates. Formula-1
Novel process for the preparation of Moxifloxacin hydrochloride through novel quinoline amide intermediate. The present invention also relates to novel process for the preparation of anhydrous crystalline form-I of Moxifloxacin hydrochloride.
A process for the preparation of the Formula (VII)
and pharmaceutically acceptable acid addition salts thereof, which comprises a) The esterification of Tetrahydro -2 -furoic acid (II) with methanol in presence of sulfuric acid b) Condensation of Methyl amino propyll,3-diamine (IV) with Tetrahydro -2- furo...
A novel process for the preparation of Fluvastatin and its intermediates Fluvastatin sodium of formula (I) is known as HMG-CoA reductase inhibitor
An improved process for the preparation of pantoptazole and its pharmaceutically acceptable salt compounds of general formula(5)
The present invention relates to an improved process for the preparation and purification of Pramipexole and its pharmaceutically acceptable salts, particularly pramipexole dihydrochloride monohydrate compound of formula-la as well as its intermediates. Pramipexole dihydrochloride monohydrate compound of formula-la ...
The present invention relates to an improved process for the preparation and purification of Trospium chloride as well as its intermediates. Trospium chloride compound of formula-1 is represented by the following structural formula
The present invention relates to an improved process for the preparation of dexlansoprazole. The present invention also relates to a process for the preparation of polymorphic forms of dexlansoprazole compound of formula-1 having the following structure.
The present invention provides an improved eco-friendly process for the preparation of memantine hydrochloride compound of formula-1. The present invention also provides a one-pot process for the preparation of memantine hydrochloride compound of fomula-1 from 1,3 -dimethyl adamantane without isolating any intermedi...
ABSTRACT
The present invention relates to a novel process for the preparation of bosentan compound of formula-1.
The present invention relates to a novel process for the preparation of Sitagliptin compound of formula-1 and its pharmaceutically acceptable salts.
The present invention relates to an improved process for the preparation of prasugrel compound of formula-1 and its pharmaceutically acceptable salts thereof.
Industrial process for Alfuzosin hydrochloride compound of formula-1 represented as below
ABSTRACT
The present invention relates to a novel and improved process for the preparation of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1 -lethal]-6,7,8 9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido-[ 1,2-a] pyrimidin-4-one (Paliperidone) represented by formula-1.
Title of the invention:
An improved Process for the preparation of Clopidogrel Hydrogen bromide Clopidogrel hydrogen bromide shown below as Formula-I
Improved Process For The Preparation Of Highly Pure Pitavastatin And Its Pharmaceutically Acceptable
ABSTRACT
The present invention relates to an improved process for the preparation of highly pure pitavastatin and its pharmaceutically acceptable salts compound of general formula-] as well as their polymorphic forms.
The present invention relates to an improved process for the preparation of pure olmesartan medoxomil compound of formula-1,
The present invention relates to an improved process for the synthesis of bosentan. The process involves the preparation of p-tert-butyl-N-[6-halo-5-(2-methoxyphenoxy)[252'-bipyrimidin]-4-yl] benzenesulfonamide or its salt and its condensation with ethylene glycol in presence of a base and a suitable solvent with or...
The present invention relates to a new salt of a drug with an amine salt, characterized in that said amine is selected from the group consisting of amine of the following formula-1,
Formula-1 Wherein each R1 and R2 are independently selected from a hydrogen atom, a straight or a branched alkyl group having 1 to 4 ...
The present invention relates to an improved process for the preparation of Aprepitant compound of formula-1 through a novel oxalate salt of 2(R)-[l-(R)-3,5-bis-(trifluoromethyl)phenyl)ethoxy]-3(S)"(4-fluoro phenyl) morpholine compound of formula-VII.
The present invention relates to an improved process for the preparation of pure ambrisentan compound of formula-1 through its novel amine salts. The present invention also relates to novel amine salts of {S)-2-hydroxy-3 -methoxy-3,3 -diphenylpropionic acid.
The present invention relates to an improved process for the preparation of high pure almotriptan compound of formula-1 and its pharmaceutically acceptable salts. The present invention also relates to novel polymorphs of almotriptan succinate and oxalate.
The present invention relates to a novel process for the preparation of methyl (+)-(S)-a-(o-cholorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)-acetate benzene sulfonic acid (clopidogrel besylate) represented as a compound of formula-1.
The present invention relates to an improved process for the preparation of zileuton represented by the structural formula-1.
The present invention relates to an improved process for the preparation of solifenacin compound of formula-1 and its succinate salt compound of formula-la comprising condensation of (R)-3-quinuclidinol with (S)-ethyl-l-phenyl-1,2,3,4-tetrahydro-2-isoquinoline carboxylate in presence of a suitable inorganic base in ...
The present invention relates to novel process for the preparation of intermediate of GABA analogue represented by the following structural formula-1
The present invention relates to an improved process for the preparation of (R)-2-acetamido-N-benzyl-3-methoxypropionamide compound of formula-1 and also relates to process for its purification.
The present invention relates to novel and improved processes for the preparation of metopimazine compound of formula-1 and its pharmaceutically acceptable salts.
The present invention relates to novel process for the preparation of sitagliptin compound of formula-1 and its pharmaceutically acceptable salts. The present invention also relates to the recovery of sitagliptin intermediates from other isomer of sitagliptin and their usage.
The present invention relates to novel salts of 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid and its intermediates used in the preparation of highly pure 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1.
The present invention relates to an improved process for the preparation of (R)-4-(2-(halomethyl)-3-methylbutyl)-l-methoxy-2-(3-methoxypropoxy) benzene compound of formula-1 and 3-amino-2,2-dimethylpropanamide compound of formula-12, useful intermediates in the synthesis of an orally active renin inhibitors.
...
The present invention relates to an improved process for the preparation of bosentan and its intermediate. The bosentan compound of formula-1 is represented by the following structural formula
The present invention is relates to polymorphs of bis[(E)-7-[4-(4- fluorophenyl)-6-iso-propyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt
The present invention relates to an improved process for the preparation of N-tert-buyl-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide and its intermediate.
The present invention relates to an improved process for the preparation of (3aRS, 12bRS)-5-Chloro-2-methyl-2,3,3a, 12b-tetrahydro- 1Hdibenzo[2,3:6,7] oxepino[4,5-c]pyrrole compound of formula-1 and its pharmaceutically acceptable salts.
ABSTRACT
The present invention relates to an improved process for the preparation of ambrisentan compound of formula-1 and its intermediates as well as their polymorphs.
ABSTRACT
The present invention relates to an improved process for the preparation of Darusentan compound of formula-1 and its polymorph.
The present invention relates to an improved process for the preparation of ranolazine compound of formula-1. It also relates to isolation and characterization of impurities, which are observed in the synthesis of ranolazine.
The present invention relates to oral solid pharmaceutical composition of RS-4-[2-dimethylamino-l-(l-hydroxycyclohexyl)ethyl]phenol and process for preparing the same.
The present invention provides a novel salts of 3-cyclopropylmethoxy-4-difluoromethoxybenzoic acid and its use in the preparation of highly pure 3-cyclopropylmethoxy-4-difluoromethoxybenzoic acid, a useful intermediate in the
preparation of 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy) be...
The present invention relates to a novel process for the preparation of ADP receptor inhibitors
The present invention relates to a process for the purification of deferasirox compound of formula-1.
A process for the preparation of 2-((4R,6S)-6-((E)-2-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)vinyl)-2,2-dimethyl-l,3-dioxan-4-yl) -N,N-disubstitutedacetamide compounds of general formula-1 containing low level of unwanted Z-isomer,wherein R and R" is independently selected from hy...
The present invention relates to process for the preparation of (R)-2-(4-methoxy-3-(3-methoxypropoxy) benzyl)-3-methylbutan-l-ol compound of formula-1, a useful intermediate in the synthesis of an orally active renin inhibitor.
The present invention relates to a novel solid pharmaceutical composition of dronedarone, its salts and process for preparing the same.
The present invention relates to novel and improved processes for the preparation of (R)-2-(3 -(diisopropylamino)-1 -phenylpropyl)-4-(hydroxymethyl)phenylisobutyrate represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.
An improved process for the preparation of 2-[3-cyano-4-(2- methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1. The present invention also provides the process for the preparation of crystalline forms A, B and G of compound of formula-1.
The present invention relates to an improved process for the preparation of trans- 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-lH-dibenz[2,3,6,7]oxepino[4,5c]pyrrol-l-one compound of formula-1.
FIG.
The present invention relates to process for the preparation of l-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]benzimidazol-5-yl-carboxylicacid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)amide methanesulfonate, represented by the following structural formula-1. Further, the present invention also provi...
The present invention relates to a process for the preparation of (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl propanamine represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.
The present invention relates to an improved process for the preparation of (R)-2-Acetamido-N-benzyl-3-methoxypropionamide represented by the following structural formula-1,
The present invention relates to an improved process for the preparation of antifungal drug i.e., 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluoro phenyl) tetrahydro-5-(lH-1,2,4-triazol-1 -ylmethyl)-3-furanyl]methoxy]phenyl]-1 -piperazinyl]phenyl]-2-[( 1 S,2S)-1 -ethyl-2-hydroxypropyl]-2,4-dihydro-3H-l,2,4-triazol-3-one c...
The present invention relates to a process for the preparation of (Z)-7[(lR,2R,3R,5S)-3,5-dihydroxy-2-[(lE,3S)-3-hydroxy-5-phenyl-l-pentenyl]cyclopentyl] 5-N-ethylheptenamide compound of formula-1 represented by the following structural formula through a novel intermediate i.e., (3aR,4R,5R,6aS)-4-((lE,3S)-3-hydroxy-...
The present invention provides an improved process for the preparation of ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-4-yl)benzamido)propanoate compound of formula-7, which is a key intermediate in the synthesis of Dabigatran etexilate mesylate compound of formula-la. The present invention also provides salts of Dab...
The present invention relates to a non-hygroscopic amorphous free-flowing powder form of (±)-4"-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-l//-l-benzazepin-l-yl)carbonyl]-o-tolu-m-toluidide represented by the following structural formula-1 and process for its preparation.
The present invention relates to an improved process for the preparation of 2-ethoxy-1 - {[2"-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl} -1H-benzimidazole-7-carboxylic acid compound of formula-2, its derivatives and their pharmaceutically acceptable salts thereof.
The present invention relates to an improved process for the preparation of (3β )-17-(3-pyridinyl)androsta-5,16-dien-3-yl acetate compound of formula-1 and its polymorphs.
Formula-1
The present invention relates to novel process for the preparation of 2-[4-(2-{4-[l-(2-
ethoxyethyl)-lH-beriziniidazol-2-yl]-l-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid
represented by the following structural formula-1.
Formula-1 The present invention also provides novel intermediate compounds useful for t...
The present invention relates to an improved process for the preparation of (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-fi-oxo-l-piperidine propanenitrile compound of formula-1 and its pharmaceutically acceptable salts.
Title of the invention:
An improved process for the preparation of Alfuzosin hydrochloride (Formula I)
Title of the invention:
An improved process for the preparation of Montelukast and its pharmaceutically acceptable salts
Montelukast sodium (Formula-I) illustrated as below
One-Pot Synthesis for the preparation of Pantoprazole and its pharmaceutically acceptable salts
Pantaprazole sodium (Formula-I) illustrated as below
An improved Process for the preparation of Clopidogrel and its pharmaceutically acceptable salts particularly Clopidogrel hydrogen chloride, Clopidogrel hydrogen bromide and Clopidogrel hydrogen sulfate Form-I.
The present invention relates to process for the preparation of D-glucitol 15- anhydro-l-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl] methyl]phenyl]- (1S) formula- 1 and its crystalline forms thereof.
The present invention relates to a process for the preparation of amorphous (1S)-1,5-anhydro-l-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol which is represented by the following structural formula-1:
The present invention relates to an improved process for the preparation of N-[4-
[(3-chloro-4-fluoropheny1)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-
‘(dimethyl amino_)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs
thereof.
The present invention relates to an improved process for the preparation of l-
[(3 R)-3 -[4-amino-3 -(4-phenoxyphenyl)- l H-pyrazolo [3 ,4-d]pyrimidin- l -yl] - l -piperidin
yl]-2-propen-1-one- compound of formulaél, which is‘represented by the following
structural formula:
The present invention relates to a process for the preparation of amorphous (R)-3-(4-(7H-pyrrólo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-cyclopentylpropanenitrile phosphate compound of formula-1 represented by the following structural formula:
The present invention relates to an improved process for the preparation of (R)-3-(4-(7H-
pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl)-3-cyclopentylpropanenitrile phosphate
compound of formula-la, represented by the following structure:
The present invention relates to a process for the preparation of isobutyric acid 2-((R)-3-dissorpropylammounium-1-phenylpropyl)-4-(hydroxymethyl) phenyl ester represented by the following structural formula-1 and its pharmaceutically acceptable salts threof.
Abstract
The present invention relates to crystalline 1,2-Propanediol solvate of N-(2-chloro-6-methylphenyl)-24[6-[4-(2-hydroxyethyl)-l-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-
thiazolecarboxamide compound of formula-1 and its process for the preparation.
The present invention relates to amorphous form of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-l-piperazinyl)propoxy]-3-quinoline carbonitrile represented by the following structural formula-1 and process for its preparation.
A process for the preparation of anhydrous type I crystals of aripiprazole consistently. Aripiprazole is represented by the following structural formula-1.
The present invention relates to an improved process for the preparation of dihydroxy protected derivatives.
Abstract
The present invention relates to an improved process for the preparation and purification of bosentan monohydrate compound of formula-1. The present invention also provides the preparation, isolation and characterization of 4-isopropyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2"-bipyrimidin-4-yl)-benz...
An improved process for pure Duloxetine hydrochloride compound of formula-1 represented as below
i :
I 1 '
ABSTRACT
! . The present invention relates to novel processes for the preparation of (S)-isopropyl 2-
((S)-(((2R3MI^R)-5<2,4-dioxo
metiiyltetrahydrofuran-2-yl)methoxy)-(phenoxy)phosphorylamino)propanoate represented by the
following structural formula-land its novel polymorph.
i
"I ...
Abstract
The .present invention relates to an improved process for the preparation of Prazosin
hydrochloride compound of formula-la, its intermediate and their novel crystalline forms
thereof.
The present invention relates to novel solvate of trityl olmesartan compound of formula-2 as well as an improved process for the preparation of highly pure olmesartan medoxomil compound of formula-1.
The present invention relates to an improved process for the preparation of deferasirox as well as a process for its purification. The present invention also relates to novel amine salts of deferasiox compound of general formula-8 and the process for their preparation.
The present invention relates to an improved process for the preparation of methyl 4,6-
diaminoTZ-[l-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3 -y1]-5—pyrimidinyl(methyl)carbamate
compound of formula-1 ,represented by the following structure:
The present invention relates to an improved process for the preparation of Azelastine compound of formula-1 and its pharmaceutically acceptable salts.
Formula-1
The present invention relates to an improved process for the preparation of prasugrel and its pharmaceutically acceptable salts, especially hydrochloride compound of formula-la. The present invention also relates to novel salts of 5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7a-hexahydrothieno[3,2-c]...
The present invention relates to an improved process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-l-(phenylmethyl)propyl]-carbamic acid (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl ester compound of formula-1 represented by the following structural formula:
...
The present invention provides a process for the preparation of form-XVI of 5-[4-[4-(5-cyano-1 H-indol-3-yl)butyl]-1 -piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula-1 represented by the following structural formula.
Formula-1
The present invention relates to novel salts of ethyl (3R,4S,5R)-4,5-imino-3-(l-ethylpropoxy)-l-cyclohexene-l-carboxylate compounds of formula-3 and an improved process for their preparation. The present invention also relates to improved process for the preparation of oseltamivir and its pharmaceutically acceptable...
The present invention relates to the processes for the preparation of (S)-5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-lH-benzimidazole sodium compound of formula-1 and bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-lH-benzimidazole-1-yl) magnesium dihydrate compound...
The present invention relates to an improved process for the preparation of [[2(S)-[[4(R)> (3-hydfbxyphen^ acid dihydrate, represented by the following structural formula:
The present invention relates to an improved process for the preparation of L3-bis(2-chloroethyl)-1 -nitrosourea compound of formual-1 which is represented by the following structural formula:
The present invention relates to an improved process for the preparation of N-[2-[(lS)-l-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-lJ3-dioxo-lH-isoindol-4-yl]acetamide represented by the following structural formula-1.
The present invention relates to an improved process for the preparation of 2-({6-[(3R)-3-aminopiperidin-1 -yl] -3 -methyl-2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl} methyl)benzonitrile represented by the following structural formula-1 and pharmaceutically acceptable salts thereof.
The present invention relates to a process for the preparation of 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-l-piperazinyl]-2-benzofuran carboxamide hydrochloride compound of formula-la and its polymorphs thereof.X
The present invention relates to an improved process for the preparation of 11 -[(Z)-3-(dimethylamino)propylidene]-6,11 -dihydrodibenzo[b,e]oxepin-2-aceticacid compound of formula-1 and its pharmaceutically acceptable salts.
The present invention relates to an improved process for the preparation of 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-d^
yl}-2-fluoro-N-methylbenzamide compound of formula-1 represented by the following formula:
The present invention relates to an improved process for the preparation of 4-[[4-[[4-[(E)-
2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
monohydrochloride compound of formula-1a; represented by the following structural.
Abstract
The present invention relates to acid addition salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4"-(trifluoromethoxy) [I,I"-biphenyl]-3-carboxamide compound of formula-1 and process for its preparation thereof. which is represented by the following structural formula
...
The present invention relates to novel crystalline polymorphs of l-[2-(2,4-dimethyl-phenylsulfanyl^phenylj-piperazine hydrobromide represented by the following structural formula-la and process for preparation thereof.
Abstract
The present invention relates to crystalline forms of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4’-(trifluoromethoxy) [1,1’-biphenyl]-3-carboxamide phosphate salts and process for the preparation thereof, represented by the following structural formula:
The present invention relates to process for the preparation of methyl 4,6-diamino-2-[l-(2-fluorobenzyl)-lH-pyrazolo[354-b]pyridin-3-yl]-5-pyrirnidinyl(methyl)carbamate and its polymorphs thereof compound of formula-1, represented by the following structure:
A process for the preparation of crystalline form-N2 of 5-chloro-N4-[2-[(l-methylethyl)
sulfonyl]phenyl] -N2- [5-methyl-2-(l
-methylethoxy)-4-(4-piperidinyl)phenyl] -2,4-
pyrimidinediamine acetic acid salt compound of formula-1b, comprising of the following
steps:
A
a) Adding acetone to
5-chloro-N4-[2-[...
Abstract
The present invention relates to an improved process for the preparation of (S)-N-[2-(l^.T^-tetrahydro^H-indeno-tS^-blfuran-S-yOethyllpropionamide compound of formula-1, represented by the following structural formula:
The present invention provides novel solid state forms of 2-((5-bromo-4-(4-
cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid of formula (I) and its
process for preparation thereof. The compound of formula (I) is represented by the following
structural formula.
The present invention relates to an improved process for the preparation of methyl 4,6-
diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl(methyl)carbamate
compound of formula-1, represented by the following structure:
The present invention relates to process for the preparation of amorphous (1S)-1,5-anhydro-l-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol compound of formula-1, represented by the following structural formula.
The present invention relates to novel crystalline polymorphs of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide represented by the following structural formula-1a and process for preparation thereof.
Formula-1a
ABSTRACT
Title: Co-amorphous form of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e] pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and process for its preparation thereof
The present invention provides co-amorphous form of (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,...
Registered Trademarks
[Class : 5] Pharmaceutical Products
[Class : 5] Pharmaceutical Products
[Class : 5] Pharmaceutical Products
View +252 more Brands for Msn Laboratories Private Limited.
Charges
30 April 2019
Axis Bank Limited
12 Lak
30 April 2019
Axis Bank Limited
11 Lak
29 April 2019
Axis Bank Limited
7 Lak
08 March 2019
Hdfc Bank Limited
167 Crore
30 October 2018
Axis Bank Limited
5 Crore
29 December 2017
Yes Bank Limited
50 Crore
21 September 2016
Axis Bank Limited
23 Lak
13 July 2016
The Hongkong And Shanghai Banking Corporation Limited
100 Crore
27 March 2015
Indusind Bank Ltd.
221 Crore
24 January 2012
Icici Bank Limited
240 Crore
25 August 2004
Axis Bank Limited
213 Crore
30 October 2014
Axis Bank Limited
17 Lak
19 August 2006
Axis Bank Limited
6 Crore
13 August 2012
Icici Bank Limited
20 Crore
27 September 2007
3i Infotech Trusteeship Services Limited
20 Crore
12 August 2010
Barclays Bank Plc
10 Crore
30 March 2009
Idbi Bank Limited
15 Crore
23 March 2021
Hdfc Bank Limited
100 Crore
01 March 2021
Axis Finance Limited
75 Crore
23 October 2020
Hdfc Bank Limited
12 Lak
23 October 2020
Hdfc Bank Limited
16 Lak
21 October 2020
Hdfc Bank Limited
9 Lak
09 January 2020
Kotak Mahindra Bank Limited
100 Crore
03 December 2019
Bajaj Finance Limited
75 Crore
04 December 2023
Axis Bank Limited
0
04 December 2023
Axis Bank Limited
0
03 November 2023
Axis Bank Limited
0
20 October 2023
Axis Bank Limited
0
01 September 2023
Axis Bank Limited
0
16 August 2023
Others
0
26 July 2023
Axis Bank Limited
0
29 June 2023
Axis Bank Limited
0
27 March 2023
Others
0
27 March 2023
Axis Bank Limited
0
27 March 2023
Axis Bank Limited
0
19 January 2023
Axis Bank Limited
0
26 December 2022
Axis Bank Limited
0
30 December 2022
Canara Bank
0
29 December 2022
Others
0
03 December 2022
Axis Bank Limited
0
28 October 2022
Axis Bank Limited
0
28 September 2022
Others
0
20 September 2022
Axis Bank Limited
0
18 August 2022
Others
0
23 August 2022
Axis Bank Limited
0
13 July 2016
The Hongkong And Shanghai Banking Corporation Limited
0
29 December 2017
Yes Bank Limited
0
17 February 2022
Bank Of India
0
11 November 2021
Others
0
30 April 2019
Axis Bank Limited
0
29 April 2019
Axis Bank Limited
0
30 April 2019
Axis Bank Limited
0
07 January 2021
Hdfc Bank Limited
0
08 March 2019
Hdfc Bank Limited
0
24 January 2012
Others
0
21 October 2020
Hdfc Bank Limited
0
23 October 2020
Hdfc Bank Limited
0
30 October 2018
Axis Bank Limited
0
01 March 2021
Others
0
23 March 2021
Hdfc Bank Limited
0
21 September 2016
Axis Bank Limited
0
27 March 2015
Others
0
03 December 2019
Others
0
25 August 2004
Axis Bank Limited
0
23 October 2020
Hdfc Bank Limited
0
09 January 2020
Others
0
30 October 2014
Axis Bank Limited
0
30 March 2009
Idbi Bank Limited
0
27 September 2007
3i Infotech Trusteeship Services Limited
0
19 August 2006
Axis Bank Limited
0
13 August 2012
Icici Bank Limited
0
12 August 2010
Barclays Bank Plc
0
08 December 2023
Axis Bank Limited
0
04 December 2023
Axis Bank Limited
0
04 December 2023
Axis Bank Limited
0
03 November 2023
Axis Bank Limited
0
20 October 2023
Axis Bank Limited
0
01 September 2023
Axis Bank Limited
0
16 August 2023
Others
0
26 July 2023
Axis Bank Limited
0
29 June 2023
Axis Bank Limited
0
27 March 2023
Others
0
27 March 2023
Axis Bank Limited
0
27 March 2023
Axis Bank Limited
0
19 January 2023
Axis Bank Limited
0
26 December 2022
Axis Bank Limited
0
30 December 2022
Canara Bank
0
29 December 2022
Others
0
03 December 2022
Axis Bank Limited
0
28 October 2022
Axis Bank Limited
0
28 September 2022
Others
0
20 September 2022
Axis Bank Limited
0
18 August 2022
Others
0
23 August 2022
Axis Bank Limited
0
13 July 2016
The Hongkong And Shanghai Banking Corporation Limited
0
29 December 2017
Yes Bank Limited
0
17 February 2022
Bank Of India
0
11 November 2021
Others
0
30 April 2019
Axis Bank Limited
0
29 April 2019
Axis Bank Limited
0
30 April 2019
Axis Bank Limited
0
07 January 2021
Hdfc Bank Limited
0
08 March 2019
Hdfc Bank Limited
0
24 January 2012
Others
0
21 October 2020
Hdfc Bank Limited
0
23 October 2020
Hdfc Bank Limited
0
30 October 2018
Axis Bank Limited
0
01 March 2021
Others
0
23 March 2021
Hdfc Bank Limited
0
21 September 2016
Axis Bank Limited
0
27 March 2015
Others
0
03 December 2019
Others
0
25 August 2004
Axis Bank Limited
0
23 October 2020
Hdfc Bank Limited
0
09 January 2020
Others
0
30 October 2014
Axis Bank Limited
0
30 March 2009
Idbi Bank Limited
0
27 September 2007
3i Infotech Trusteeship Services Limited
0
19 August 2006
Axis Bank Limited
0
13 August 2012
Icici Bank Limited
0
12 August 2010
Barclays Bank Plc
0
08 December 2023
Axis Bank Limited
0
04 December 2023
Axis Bank Limited
0
04 December 2023
Axis Bank Limited
0
03 November 2023
Axis Bank Limited
0
20 October 2023
Axis Bank Limited
0
01 September 2023
Axis Bank Limited
0
16 August 2023
Others
0
26 July 2023
Axis Bank Limited
0
29 June 2023
Axis Bank Limited
0
27 March 2023
Others
0
27 March 2023
Axis Bank Limited
0
27 March 2023
Axis Bank Limited
0
19 January 2023
Axis Bank Limited
0
26 December 2022
Axis Bank Limited
0
30 December 2022
Canara Bank
0
29 December 2022
Others
0
03 December 2022
Axis Bank Limited
0
28 October 2022
Axis Bank Limited
0
28 September 2022
Others
0
20 September 2022
Axis Bank Limited
0
18 August 2022
Others
0
23 August 2022
Axis Bank Limited
0
13 July 2016
The Hongkong And Shanghai Banking Corporation Limited
0
29 December 2017
Yes Bank Limited
0
17 February 2022
Bank Of India
0
11 November 2021
Others
0
30 April 2019
Axis Bank Limited
0
29 April 2019
Axis Bank Limited
0
30 April 2019
Axis Bank Limited
0
07 January 2021
Hdfc Bank Limited
0
08 March 2019
Hdfc Bank Limited
0
24 January 2012
Others
0
21 October 2020
Hdfc Bank Limited
0
23 October 2020
Hdfc Bank Limited
0
30 October 2018
Axis Bank Limited
0
01 March 2021
Others
0
23 March 2021
Hdfc Bank Limited
0
21 September 2016
Axis Bank Limited
0
27 March 2015
Others
0
03 December 2019
Others
0
25 August 2004
Axis Bank Limited
0
23 October 2020
Hdfc Bank Limited
0
09 January 2020
Others
0
30 October 2014
Axis Bank Limited
0
30 March 2009
Idbi Bank Limited
0
27 September 2007
3i Infotech Trusteeship Services Limited
0
19 August 2006
Axis Bank Limited
0
13 August 2012
Icici Bank Limited
0
12 August 2010
Barclays Bank Plc
0
Documents
Form CHG-1-27022021-signed
CERTIFICATE OF REGISTRATION OF CHARGE-20210227
Form CHG-1-26022021-signed
CERTIFICATE OF REGISTRATION OF CHARGE-20210226
Form DPT-3-08012021_signed
Instrument(s) of creation or modification of charge;-30122020
Optional Attachment-(2)-30122020
Optional Attachment-(1)-30122020
Instrument(s) of creation or modification of charge;-24122020
Optional Attachment-(1)-24122020
Form CHG-1-24122020_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201224
Form CHG-1-02122020_signed
Instrument(s) of creation or modification of charge;-02122020
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201202
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201110
Form CHG-1-11112020_signed
Optional Attachment-(1)-11112020
Instrument(s) of creation or modification of charge;-11112020
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201111
Instrument(s) of creation or modification of charge;-10112020
Optional Attachment-(1)-10112020
Form CHG-1-10112020
Form CHG-1-06112020_signed
Optional Attachment-(1)-06112020
Instrument(s) of creation or modification of charge;-06112020
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201106
Optional Attachment-(1)-19102020
Form CHG-1-19102020_signed
Instrument(s) of creation or modification of charge;-19102020
